We found the design of their study to be strikingly similar to our initial randomized, double-blind, placebo-controlled study of atropine and glycopyrrolate published in 2000 within this same journal (July 2000).2 The only real difference between our study and the Malik study published 9 years later was the total number of patients enrolled; in fact, the findings are nearly identical. We designed our initial study to have 80% statistical power (β) of detecting a 12% difference between the mean values recorded on a visual analog scale for the primary end point of control of respiratory tract secretions. This difference was estimated to be the minimum required to make the use of these medications clinically important. To achieve this level of power, approximately 210 patients were calculated to have been required for the study, 70 in each group. Although Malik and colleagues enrolled 1,000 consecutive patients who were eligible, they unfortunately did not report the level of statistical power to which they designed their study. If they did, one would likely see that the minimal difference in visual analog scale scores reported was barely statistically significant, and hardly clinically generalizable.